Beyond accuracy, the model provided detailed mechanistic reasoning, abbreviated here: “Atezolizumab is an anti-PD-L1 monoclonal antibody that blocks this interaction, thereby restoring T-cell function and enhancing the immune response against cancer cells. Here, CD274 is linked to cancer.